StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Adjusted Operating Margin Ratio — Non-GAAP by Quarter

Adjusted Operating Margin Ratio — Non-GAAP (%) (%)

AbbVie Adjusted Operating Margin Ratio — Non-GAAP: 48.3% in Q2 2026, up 4.0 pts from a year earlier.

Latest, Q2 2026
48.3%
Period ended Jun 30, 2026
Change on a year earlier
+4.0 pts
44.3% in Q2 2025
History
33 quarters
Since Q4 2017
Sources
33
Documents cited below

Where the Q2 2026 figure comes from

“On a GAAP basis, the operating margin ratio in the second quarter was 37.9 percent. The adjusted operating margin ratio was 48.3 percent”

Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗

Reported in Form 8-K Earnings Release.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAdjusted Operating Margin Ratio — Non-GAAP (%) (%)Year on yearSource
Q2 2026Jun 30, 202648.3%+4.0 ptsForm 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Q1 2026Mar 31, 202640.8%-1.5 ptsForm 8-K (abbv-20260331xexhibit991.htm, filed 2026-04-29) ↗
Q4 2025Dec 31, 202538.3%+3.6 ptsForm 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 202530.9%-15.8 ptsForm 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗
Q2 2025Jun 30, 202544.3%+1.7 ptsForm 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗
Q1 2025Mar 31, 202542.3%+0.1 ptsForm 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗
Q4 2024Dec 31, 202434.7%-9.1 ptsForm 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
Q3 2024Sep 30, 202446.7%0.0 ptsForm 8-K (abbv-20240930xexhibit991.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 202442.6%-4.4 ptsForm 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗
Q1 2024Mar 31, 202442.2%-2.8 ptsForm 8-K (abbv-20240331xexhibit991.htm, filed 2024-04-26) ↗
Q4 2023Dec 31, 202343.8%-8.3 ptsForm 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
Q3 2023Sep 30, 202346.7%-6.7 ptsForm 8-K (abbv-20230930xexhibit991.htm, filed 2023-10-27) ↗
Q2 2023Jun 30, 202347.0%-4.0 ptsForm 8-K (abbv-20230630xexhibit991.htm, filed 2023-07-27) ↗
Q1 2023Mar 31, 202345.0%-6.4 ptsForm 8-K (abbv-20230331xexhibit991.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 202252.1%+2.8 ptsForm 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗
Q3 2022Sep 30, 202253.4%+2.3 ptsForm 8-K (abbv-20220930xexhibit991.htm, filed 2022-10-28) ↗

Breakdown

What makes up adjusted Operating Margin Ratio — Non-GAAP

Cite this data

StockData. (2026). AbbVie Adjusted Operating Margin Ratio — Non-GAAP (%), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/margin-adj-om

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.